INSUBCONTINENT EXCLUSIVE:
If the researchers, executives and investors behind Coda Biotherapeutics have their way, one day soon there really could be a cure for
neurological diseases starting with severe pain and epilepsy.America is a country in pain
And over the past 20 years the doctors treating those Americans and the drug companies developing therapies for them have managed to turn
Centers for Disease Control
University and a former White House drug-policy adviser, told the journal Nature.As the pain epidemic and attendant opioid crisis began to
skyrocket, several companies have been racing to find alternatives to the drug treatments that were now killing Americans by the thousands
Other approaches like electrical nerve stimulation can carry risks, and invasive surgeries are an unappealing last resort, according to
receptors in the sensory neurons that provide signals to the brain about physical stimuli
Those receptors can be unlocked by small-molecule drugs, which would instruct the sensory neurons to stop firing, thereby cutting off the
drug pairs that were developed and tested for their pharmacological and toxicological effects, but discarded because of a lack of efficacy,
Versant Ventures, MPM Capital and Astellas Venture Management, have doubled down on their initial $19 million commitment to the new drug
Woiwode, PhD, managing director at Versant Ventures and Coda Chairman, in a statement
The company is also working on therapies that can reduce the severity of epilepsy for the nearly 3.4 million people in the United States
manifestations of the condition, and is linked to a specific region of the brain.By engineering neurotransmitter receptors that are
activated by medicines that can be taken orally, Coda thinks it can control the activity of neurons responsible for both chronic pain and
